Search clinical trials for: albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin

Total 1173 results

Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions
Fifth Affiliated Hospital, Sun Yat-Sen University
Dongguan People's Hospital

Recruiting

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Treatment

China
Guizhou Medical University

Unknown

Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC

Efficacy and Safety

China
The First Affiliated Hospital of Zhengzhou University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma
Emory University
National Cancer Institute (NCI)

Active, not recruiting

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
Sorrento Therapeutics, Inc.

Completed

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer (TRIBECA)

Metastatic Breast Cancer | Locally Recurrent Breast Cancer

United States, Georgia, Moldova, Republic of, Romania, Serbia, Singapore, Ukraine
Jiuda Zhao

Recruiting

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Intrahepatic Cholangiocarcinoma | Gallbladder Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Malignant Neoplasm in the Peritoneum | Distal Bile Duct Adenocarcinoma | Stage IV Distal Bile Duct Cancer AJCC v8 | Stage IV Intrahepatic Bile Duct Cancer AJCC v8 | Stage IVB Gallbladder...

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Epithelial Cancer | Brenner Tumor | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer | Ovarian Mucinous... and other conditions

United States
Tang-Du Hospital

Recruiting

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Locally Advanced Cervical Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Stage II Pancreatic Cancer AJCC v6 and v7 | Stage IIA Pancreatic Cancer AJCC v6 and v7 | Stage IIB Pancreatic Cancer AJCC v6 and...

United States
Guangzhou Institute of Respiratory Disease
Jiangsu HengRui Medicine Co., Ltd.; BGI-Shenzhen

Completed

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Immunotherapy

China
Shengjing Hospital

Recruiting

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Breast Cancer

China
Peking University Cancer Hospital & Institute

Active, not recruiting

Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast Cancer

Breast Cancer

China
Tongji Hospital

Unknown

Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer (T+TP)

Esophagus Cancer

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Unresectable Extrahepatic... and other conditions

United States
Fudan University

Active, not recruiting

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (SPARK)

Metastatic Breast Cancer

China
Canadian Cancer Trials Group
Celgene; Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Completed

Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.

Urothelial Cancer

Canada, Australia
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Celgene

Active, not recruiting

Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer

Resectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
National Comprehensive Cancer Network

Completed

Hepatic Arterial Infusion (HAI) of Abraxane

Solid Tumors | Liver Cancer | Advanced Cancers

United States
M.D. Anderson Cancer Center

Recruiting

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid Neoplasm | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage... and other conditions

United States
China Medical University, China

Recruiting

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Gastric Carcinoma

China
Ohio State University Comprehensive Cancer Center
Celgene Corporation; National Comprehensive Cancer Network

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

Intraocular Melanoma

United States
Fujian Medical University Union Hospital

Not yet recruiting

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

Chemotherapy | Radiation Therapy

China
First People's Hospital of Foshan

Not yet recruiting

Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms
Guangdong Association of Clinical Trials

Not yet recruiting

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Non-Small-Cell Lung Cancer
University of Washington
National Cancer Institute (NCI)

Completed

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | Skin Metastases

United States
Taipei Veterans General Hospital, Taiwan

Completed

Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

Non-small-cell Lung Cancer

Taiwan
Cancer Institute and Hospital, Chinese Academy...

Unknown

Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer (CSAPPPCC)

Uterine Cervical Cancer

China
Qilu Hospital of Shandong University

Withdrawn

Neoadjuvant Immunotherapy to ESCC

Esophagus SCC

China
Institut fuer Frauengesundheit
GlaxoSmithKline; Schantl Pharma Service, Germany

Unknown

Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma (AGO-Zervix-1)

Recurrent, Persistent or Metastasized Cervical Cancer

Germany
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC (Compass-001)

Non-Small Cell Lung Cancer

China
Tang-Du Hospital

Active, not recruiting

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

Non-small-cell Lung Cancer (NSCLC)

China
Beijing Tongren Hospital

Not yet recruiting

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

Head and Neck Squamous Cell Carcinoma
Celgene

Completed

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Melanoma | Sarcoma, Soft Tissue | Cancer | Fibrosarcoma | Neuroblastoma | Osteogenic Sarcoma | Rhabdomyosarcoma | Neoplasm | Malignant Melanoma | Tumors | Histiocytoma | Dermatofibrosarcoma | Sarcoma, Ewing's | Neoplasia | Ewing's Sarcoma | Ewing's Tumor | Sarcomas, Epitheliod | Sarcoma, Spindle Cell | Clinical Oncology | Oncology,... and other conditions

United States, Canada, Spain, France, United Kingdom, Italy, Switzerland
University of Texas Southwestern Medical Center
Celgene

Completed

Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC

STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER

United States
Shanghai Zhongshan Hospital
Fudan University

Recruiting

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Unresectable Locally Advanced or Metastatic Pancreatic Cancer

China
National Health Research Institutes, Taiwan
National Taiwan University Hospital; National Cheng-Kung University Hospital

Completed

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers (SOLAR)

Gastric Cancer in Situ | Pancreatic Cancers | Biliary Cancers

Taiwan
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hutchmed

Recruiting

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

China
Qilu Pharmaceutical Co., Ltd.

Unknown

A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

China
Akeso

Recruiting

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Metastatic Triple-negative Breast Cancer | Locally Advanced Triple-negative Breast Cancer

China
AIO-Studien-gGmbH
Celgene; ClinAssess GmbH

Completed

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer (NEONAX)

Resectable Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

Germany
Hebei Medical University Fourth Hospital
Beijing 302 Hospital; CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Triple Negative Breast Cancer | Nab-paclitaxel

China
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

Trial of TP Versus TC Regimens for Stage IVb, Persistent, or Recurrent Cervical Cancer (JCOG0505, CC-TPTC-P3)

Uterine Cervical Neoplasms

Japan
Huazhong University of Science and Technology

Active, not recruiting

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

China

Search clinical trials for: albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations